Tranilast: a potential anti-Inflammatory and NLRP3 inflammasome inhibitor drug for COVID-19

References

• Cui J, Li F, Shi Z-L. Origin and evolution of pathogenic Coronaviruses. Nat Rev Microbiol. 2019;17(3):181–192.
   PubMed Web of Science ®Google Scholar
• Gralinski LE, Menachery VD. Return of the Coronavirus: 2019-nCoV. Viruses. 2020;12(2):135.
   PubMed Web of Science ®Google Scholar
• Skariyachan S, Challapilli SB, Packirisamy S, et al. Recent aspects on the pathogenesis mechanism, animal models and novel therapeutic interventions for Middle East respiratory syndrome coronavirus infections. Front Microbiol. 2019;10:569.
   PubMed Web of Science ®Google Scholar
• Rockx B, Kuiken T, Herfst S, et al. Comparative pathogenesis Of COVID-19, MERS And SARS In A Non-Human Primate Model. bioRxiv. 2020.
   PubMedGoogle Scholar
• Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579(7798):265–269.
   PubMed Web of Science ®Google Scholar
• Zhou P, Yang X-L, Wang X-G, et al. A pneumonia outbreak associated with a new Coronavirus of probable bat origin. Nature. 2020;579(7798):270–273.
   PubMed Web of Science ®Google Scholar
• van den Berg DF, Te Velde AA. Severe COVID-19: NLRP3 inflammasome dysregulated. Front Immunol. 2020;11:1580.
   PubMed Web of Science ®Google Scholar
• Freeman TL, Swartz TH. Targeting the NLRP3 inflammasome in severe COVID-19. Front Immunol. 2020;11:1518.
   PubMed Web of Science ®Google Scholar
• Bertocchi I, Foglietta F, Collotta D, et al. The hidden role of NLRP3 inflammasome in obesity-related COVID-19 exacerbations: lessons for drug repurposing. Br J Pharmacol. 2020;177(21):4921–4930.
   PubMed Web of Science ®Google Scholar
• Darakhshan S, Pour AB. Tranilast: a review of its therapeutic applications. Pharmacol Res. 2015;91:15–28.
   PubMed Web of Science ®Google Scholar
• Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. Jama. 2020;323(11):1061.
   PubMed Web of Science ®Google Scholar
• Yang L, Liu S, Liu J, et al. COVID-19: immunopathogenesis and immunotherapeutics. Signal Transduct Target Ther. 2020;5(1):128.
   PubMed Web of Science ®Google Scholar
• Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8(4):420–422.
   PubMed Web of Science ®Google Scholar
• Diao B, Wang C, Tan Y, et al. Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19). Front Immunol. 2020;11:827.
   PubMed Web of Science ®Google Scholar
• Zheng M, Gao Y, Wang G, et al. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol Immunol. 2020;17(5):533–535.
   PubMed Web of Science ®Google Scholar
• Tan L, Wang Q, Zhang D, et al. Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study. Signal Transduct Target Ther. 2020;5(1):33.
   PubMed Web of Science ®Google Scholar
• Zhao J, Yuan Q, Wang H, et al. Antibody responses to SARS-CoV-2 in patients with Novel Coronavirus Disease 2019. Clin Infect Dis. 2020;71(16):2027–2034.
   PubMed Web of Science ®Google Scholar
• Long Q-X, Liu B-Z, Deng H-J, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med. 2020;26(6):845–848.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-Ocampo E, et al. Clinical, laboratory and imaging features of COVID-19: a systematic review and meta-analysis. Travel Med Infect Dis. 2020;34:101623.
   PubMed Web of Science ®Google Scholar
• Zhang R, Wang X, Ni L, et al. COVID-19: melatonin as a potential adjuvant treatment. Life Sci. 2020; 250:117583.
   PubMed Web of Science ®Google Scholar
• Li X, Geng M, Peng Y, et al. Molecular immune pathogenesis and diagnosis of COVID-19. J Pharm Anal. 2020;10(2):102–108.
   PubMed Web of Science ®Google Scholar
• Li YC, Bai WZ, Hashikawa T. The neuroinvasive potential of SARS‐CoV2 may be at least partially responsible for the respiratory failure of COVID‐19 patients. J Med Virol. 2020;92(6):552–555.
   PubMed Web of Science ®Google Scholar
• Baig AM, Khaleeq A, Ali U, et al. Evidence of the COVID-19 virus targeting the CNS: tissue distribution, host–virus interaction, and proposed neurotropic mechanisms. ACS Chem Neurosci. 2020;11(7):995–998.
   PubMed Web of Science ®Google Scholar
• Ong J, Young BE, Ong S. COVID-19 in gastroenterology: a clinical perspective. Gut. 2020;69(6):1144–1145.
   PubMed Web of Science ®Google Scholar
• Zhang C, Shi L, Wang F-S. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol. 2020;5(5):428–430.
   PubMed Web of Science ®Google Scholar
• Grommes J, Soehnlein O. Contribution of neutrophils to acute lung injury. Mol Med. 2011;17(3–4):293–307.
   PubMed Web of Science ®Google Scholar
• Prompetchara E, Ketloy C, Palaga T. Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic. Asian Pac J Allergy Immunol. 2020;38:1–9.
   PubMed Web of Science ®Google Scholar
• Jiang Z, Chen Z, Hu L, et al. Calreticulin blockade attenuates murine acute lung injury by inducing polarization of M2 subtype macrophages. Front Immunol. 2020;11:11.
   PubMed Web of Science ®Google Scholar
• Chen Y, Li R, Wang Z, et al. Dehydrocostus lactone inhibits NLRP3 inflammasome activation by blocking ASC oligomerization and prevents LPS-mediated inflammation in vivo. Cellular Immunology. 2020;349:104046.
   PubMed Web of Science ®Google Scholar
• Hou X, Xu G, Wang Z, et al. Glaucocalyxin A alleviates LPS-mediated septic shock and inflammation via inhibiting NLRP3 inflammasome activation. Int Immunopharmacol. 2020;81:106271.
   PubMed Web of Science ®Google Scholar
• Nosaka N, Martinon D, Moreira D, et al. Autophagy protects against developing increased lung permeability and hypoxemia by down regulating inflammasome activity and IL-1β in LPS plus mechanical ventilation-induced acute lung injury. Front Immunol. 2020;11:207.
   PubMed Web of Science ®Google Scholar
• Petrilli V, Papin S, Dostert C, et al. Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration. Cell Death Differentiation. 2007;14(9):1583–1589.
   PubMed Web of Science ®Google Scholar
• Ichinohe T, Pang IK, Iwasaki A. Influenza virus activates inflammasomes via its intracellular M2 ion channel. Nat Immunol. 2010;11(5):404.
   PubMed Web of Science ®Google Scholar
• Gonzalez ME, Carrasco L. Viroporins. FEBS Lett. 2003;552(1):28–34.
   PubMed Web of Science ®Google Scholar
• Ito M, Yanagi Y, Ichinohe T. Encephalomyocarditis virus viroporin 2B activates NLRP3 inflammasome. PLoS Pathog. 2012;8(8):e1002857.
   PubMed Web of Science ®Google Scholar
• Triantafilou K, Kar S, Vakakis E, et al. Human respiratory syncytial virus viroporin SH: a viral recognition pathway used by the host to signal inflammasome activation. Thorax. 2013;68(1):66–75.
   PubMed Web of Science ®Google Scholar
• Triantafilou K, Kar S, van Kuppeveld FJ, et al. Rhinovirus-induced calcium flux triggers NLRP3 and NLRC5 activation in bronchial cells. Am J Respir Cell Mol Biol. 2013;49(6):923–934.
   PubMed Web of Science ®Google Scholar
• Chen I-Y, Moriyama M, Chang M-F, et al. Severe acute respiratory syndrome coronavirus viroporin 3a activates the NLRP3 inflammasome. Front Microbiol. 2019;10:50.
   PubMed Web of Science ®Google Scholar
• Shi C-S, Nabar NR, Huang N-N, et al. SARS-Coronavirus open reading frame-8b triggers intracellular stress pathways and activates NLRP3 inflammasomes. Cell Death Discov. 2019;5(1):1–12.
   Google Scholar
• Rahim I, Djerdjouri B, Sayed RK, et al. Melatonin administration to wild‐type mice and nontreated NLRP 3 mutant mice share similar inhibition of the inflammatory response during sepsis. J Pineal Res. 2017;63(1):e12410.
   Web of Science ®Google Scholar
• Zahid A, Li B, Kombe JK, et al. Pharmacological Inhibitors of the NLRP3 Inflammasome. Front Immunol. 2019;10:2538.
   PubMed Web of Science ®Google Scholar
• Swanson KV, Deng M, Ting JP-Y. The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nat Rev Immunol. 2019;19(8):477–489.
   PubMed Web of Science ®Google Scholar
• Dinarello CA, Simon A, Van Der Meer JW. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discovery. 2012;11(8):633–652.
   PubMed Web of Science ®Google Scholar
• Ozaki E, Campbell M, Doyle SL. Targeting the NLRP3 inflammasome in chronic inflammatory diseases: current perspectives. J Inflam Res. 2015;8:15–27.
   PubMed Web of Science ®Google Scholar
• Brydges SD, Mueller JL, McGeough MD, et al. Inflammasome-mediated disease animal models reveal roles for innate but not adaptive immunity. Immunity. 2009;30(6):875–887.
   PubMed Web of Science ®Google Scholar
• Laliberte RE, Perregaux DG, Hoth LR, et al. Glutathione S-transferase omega 1-1 is a target of cytokine release inhibitory drugs and may be responsible for their effect on interleukin-1β posttranslational processing. J Biol Chem. 2003;278(19):16567–16578.
   PubMed Web of Science ®Google Scholar
• Coll RC, Robertson AA, Chae JJ, et al. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat Med. 2015;21(3):248.
   PubMed Web of Science ®Google Scholar
• Dempsey C, Araiz AR, Bryson K, et al. Inhibiting the NLRP3 inflammasome with MCC950 promotes non-phlogistic clearance of amyloid-β and cognitive function in APP/PS1 mice. Brain, Behav Immun. 2017;61:306–316.
   PubMed Web of Science ®Google Scholar
• Ismael S, Nasoohi S, Ishrat T. MCC950, the selective NLRP3 inflammasome inhibitor protects mice against traumatic brain injury. J Neurotrauma. 2018;35:1294–1303.
   PubMed Web of Science ®Google Scholar
• van der Heijden T, Kritikou E, Venema W, et al. NLRP3 inflammasome inhibition by MCC950 reduces atherosclerotic lesion development in apolipoprotein E–deficient mice—brief report. Arterioscler Thromb Vasc Biol. 2017;37(8):1457–1461.
   PubMed Web of Science ®Google Scholar
• Monnerat G, Alarcón ML, Vasconcellos LR, et al. Macrophage-dependent IL-1β production induces cardiac arrhythmias in diabetic mice. Nat Commun. 2016;7(1):1–15.
   Google Scholar
• Van Hout GP, Bosch L, Ellenbroek GH, et al. The selective NLRP3-inflammasome inhibitor MCC950 reduces infarct size and preserves cardiac function in a pig model of myocardial infarction. Euro Heart J. 2017;38(11):828–836.
   PubMed Web of Science ®Google Scholar
• Zhai Y, Meng X, Ye T, et al. Inhibiting the NLRP3 inflammasome activation with MCC950 ameliorates diabetic encephalopathy in db/db mice. Molecules. 2018;23(3):522.
   Web of Science ®Google Scholar
• Mridha AR, Wree A, Robertson AA, et al. NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice. J Hepatol. 2017;66(5):1037–1046.
   PubMed Web of Science ®Google Scholar
• Perera AP, Fernando R, Shinde T, et al. MCC950, a specific small molecule inhibitor of NLRP3 inflammasome attenuates colonic inflammation in spontaneous colitis mice. Sci Rep. 2018;8(1):1–15.
   PubMedGoogle Scholar
• Mangan MS, Olhava EJ, Roush WR, et al. Targeting the NLRP3 inflammasome in inflammatory diseases. Nat Rev Drug Discov. 2018;17(8):588–606.
   PubMed Web of Science ®Google Scholar
• Huang Y, Jiang H, Chen Y, et al. Tranilast directly targets NLRP3 to treat inflammasome‐driven diseases. EMBO Mol Med. 2018;10(4):e8689.
   PubMed Web of Science ®Google Scholar
• Bertocchi I, Foglietta F, Collotta D, et al. The hidden role of NLRP3 inflammasome in obesity‐related COVID‐19 exacerbations: lessons for drug repurposing. Br J Pharmacol. 2020;177(21):4921–4930.
   PubMed Web of Science ®Google Scholar
• Kroemer A, Khan K, Plassmeyer M, et al. Inflammasome activation and pyroptosis in lymphopenic liver patients with COVID-19. J Hepatol. 2020;73(5):1258–1262.
   PubMed Web of Science ®Google Scholar
• Hamis SJ, Macfarlane Fr A. single-cell mathematical model of SARS-CoV-2 induced pyroptosis and the anti-inflammatory response to the drug tranilast. arXiv preprint arXiv:200804172. 2020.
   Google Scholar
• Kaplansky G, Bongrand P. Cytokines and chemokines. Cell Mol Biol. 2001;47(4):569–574.
   PubMed Web of Science ®Google Scholar
• Amedei A, Prisco D. The use of cytokines and chemokines in the cancer immunotherapy. Recent Pat Anticancer Drug Discov. 2013;8(2):126–142.
   PubMed Web of Science ®Google Scholar
• Turner MD, Nedjai B, Hurst T, et al. Cytokines and chemokines: at the crossroads of cell signalling and inflammatory disease. Biochimica et Biophysica Acta (BBA)-Mol Cell Res. 2014;1843(11):2563–2582.
   PubMed Web of Science ®Google Scholar
• Hiraide S, Yanagawa Y, Iizuka K. Tranilast inhibits interleukin-33 production by macrophages. Eur J Pharmacol. 2018;818:235–240.
   PubMed Web of Science ®Google Scholar
• Tsuji K, Fukuda K, Fukushima A. Inhibition by Tranilast of the synergistic induction of degranulation and IL-13 expression by IL-33 and FcvarepsilonRI cross-linking in mast cells. Ocul Immunol Inflamm. 2017;25(6):841–843.
   PubMed Web of Science ®Google Scholar
• Xu Z-S, Shu T, Kang L, et al. Temporal profiling of plasma cytokines, chemokines and growth factors from mild, severe and fatal COVID-19 patients. Signal Transduct Targ Ther. 2020;5(1):100.
   PubMed Web of Science ®Google Scholar
• Kawamoto H, Iwatsuki K, Kurimoto S, et al. Interleukin-6 secretion by fibroblasts in carpal tunnel syndrome patients is associated with trigger finger and inhibited by tranilast. Muscle Nerve. 2020;61(3):408–415.
   PubMed Web of Science ®Google Scholar
• Nader MA, Gameil N, Abdelaziz RR, et al. Effect of tranilast in comparison with beclomethasone in chronic murine model of asthma. Exp Lung Res. 2016;42(6):296–306. Aug
   PubMed Web of Science ®Google Scholar
• Hiratochi M, Takamoto M, Tatemichi S, et al. Inhibition of interleukin 5 production with no influence on interleukin 4 production by an anti-allergic drug, tranilast, in Toxocara canis-infected mice. Int J Immunopharmacol. 2000;22(6):463–471.
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Wechsler ME. Role of eosinophils in airway inflammation of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2018;13:335–349.
   PubMed Web of Science ®Google Scholar
• Bian H, Zheng Z-H, Wei D, et al. Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial. MedRxiv. 2020.
   Google Scholar
• Menter T, Haslbauer JD, Nienhold R, et al. Post‐mortem examination of COVID19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings of lungs and other organs suggesting vascular dysfunction. Histopathology. 2020;77(2):198–209.
   PubMed Web of Science ®Google Scholar
• Liu Y, Kan M, Li A, et al. Inhibitory effects of Tranilast on cytokine, chemokine, adhesion molecule, and matrix metalloproteinase expression in human corneal fibroblasts exposed to Poly(I:C). Curr Eye Res. 2016;41(11):1400–1407.
   PubMed Web of Science ®Google Scholar
• Görg B, Karababa A, Häussinger D. Hepatic encephalopathy and astrocyte senescence. J Clin Exp Hepatol. 2018;8(3):294–300.
   PubMed Web of Science ®Google Scholar
• Azhari H, Swain MG. Role of peripheral inflammation in hepatic encephalopathy. J Clin Exp Hepatol. 2018;8(3):281–285.
   PubMed Web of Science ®Google Scholar
• Abdelaziz RR, Elkashef WF, Said E. Tranilast reduces serum IL-6 and IL-13 and protects against thioacetamide-induced acute liver injury and hepatic encephalopathy. Environ Toxicol Pharmacol. 2015;40(1):259–267.
   PubMed Web of Science ®Google Scholar
• Hertenstein A, Schumacher T, Litzenburger U, et al. Suppression of human CD4+ T cell activation by 3,4-dimethoxycinnamonyl-anthranilic acid (tranilast) is mediated by CXCL9 and CXCL10. Biochem Pharmacol. 2011;82(6):632–641.
   PubMed Web of Science ®Google Scholar
• Adachi T, Fukuda K, Kondo Y, et al. Inhibition by tranilast of the cytokine-induced expression of chemokines and the adhesion molecule VCAM-1 in human corneal fibroblasts. Invest Ophthalmol Vis Sci. 2010;51(8):3954–3960.
   PubMed Web of Science ®Google Scholar
• Chen W. A potential treatment of COVID-19 with TGF-β blockade. Int J Biol Sci. 2020;16(11):1954–1955.
   PubMed Web of Science ®Google Scholar
• Namazi MR, Soma J. Tranilast: a novel weapon against insulin resistance. Med Hypotheses. 2005;64(6):1135–1137.
   PubMed Web of Science ®Google Scholar
• Chikaraishi A, Hirahashi J, Takase O, et al. Tranilast inhibits interleukin-1β-induced monocyte chemoattractant protein-1 expression in rat mesangial cells. Eur J Pharmacol. 2001;427(2):151–158.
   PubMed Web of Science ®Google Scholar
• Kagitani S, Ueno H, Hirade S, et al. Tranilast attenuates myocardial fibrosis in association with suppression of monocyte/macrophage infiltration in DOCA/salt hypertensive rats. J Hypertens. 2004;22(5):1007–1015.
   PubMed Web of Science ®Google Scholar
• Xu X, Han M, Li T, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci. 2020;117(20):10970–10975.
   PubMed Web of Science ®Google Scholar
• Chu H, Chan JF-W, Wang Y, et al. Comparative replication and immune activation profiles of SARS-CoV-2 and SARS-CoV in human lungs: an ex vivo study with implications for the pathogenesis of COVID-19. Clin Infect Dis. 2020;71(6):1400–1409.
   PubMed Web of Science ®Google Scholar
• Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel Coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.
   PubMed Web of Science ®Google Scholar
• Catanzaro M, Fagiani F, Racchi M, et al. Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2. Sig Transduct Target Ther. 2020;5(1):1–10.
   PubMed Web of Science ®Google Scholar
• Mukai S, Ogawa Y, Saya H, et al. Therapeutic potential of tranilast for the treatment of chronic graft-versus-host disease in mice. PLoS One. 2018;13(10):e0203742.
   PubMed Web of Science ®Google Scholar
• Zhou R, Tardivel A, Thorens B, et al. Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat Immunol. 2010;11(2):136.
   PubMed Web of Science ®Google Scholar
• Deng H, Chen F, Wang Y, et al. The role of activated NLRP3 inflammatory body in acute kidney injury in rats caused by sepsis and NLRP3-TXNIP signaling pathway. Saudi J Biol Sci. 2020;27(5):1251–1259.
   PubMed Web of Science ®Google Scholar
• Muri J, Thut H, Feng Q, et al. Thioredoxin-1 distinctly promotes NF-κB target DNA binding and NLRP3 inflammasome activation independently of Txnip. eLife. 2020;9:9.
   Web of Science ®Google Scholar
• Tao Y, Hu L, Li S, et al. Tranilast prevents the progression of chronic cyclosporine nephrotoxicity through regulation of transforming growth factor β/Smad pathways. Transplant Proc. 2011;43(5):1985–1988.
   PubMed Web of Science ®Google Scholar
• Zhuo Y, Zhuo J. Tranilast treatment attenuates cerebral ischemia-reperfusion injury in rats through the inhibition of inflammatory responses mediated by NF-κB and PPARs. Clin Transl Sci. 2019;12(2):196–202.
   PubMed Web of Science ®Google Scholar
• Bluher M, Engeli S, Kloting N, et al. Hormones, autacoids, neurotransmitters and growth factors. J Pharmacol Exp Ther. 2006;318:563–570.
   PubMedGoogle Scholar
• Wójtowicz S, Strosznajder AK, Jeżyna M, et al. The Novel role of PPAR Alpha in the Brain: promising target in therapy of Alzheimer’s disease and other neurodegenerative disorders. Neurochem Res. 2020;45(5):972–917.
   PubMed Web of Science ®Google Scholar
• Liu Y, Xu D, Li J, et al. Inhibition of interleukin-1β-induced matrix metalloproteinase expression in human corneal fibroblasts by tranilast. Curr Eye Res. 2014;39(9):885–893.
   PubMed Web of Science ®Google Scholar
• Saha RN, Pahan K. Regulation of inducible nitric oxide synthase gene in glial cells. Antioxid Redox Signal. 2006;8(5–6):929–947.
   PubMed Web of Science ®Google Scholar
• Platten M, Wick W, Wischhusen J, et al. N-[3, 4-dimethoxycinnamoyl]‐anthranilic acid (tranilast) suppresses microglial inducible nitric oxide synthase (iNOS) expression and activity induced by interferon‐γ (IFN‐γ). Br J Pharmacol. 2001;134(6):1279–1284.
   PubMed Web of Science ®Google Scholar
• Spiecker M, Lorenz I, Marx N, et al. Tranilast inhibits cytokine-induced nuclear factor κB activation in vascular endothelial cells. Mol Pharmacol. 2002;62(4):856–863.
   PubMed Web of Science ®Google Scholar
• D’Alicandro V, Romania P, Melaiu O, et al. Role of genetic variations on MHC class I antigen-processing genes in human cancer and viral-mediated diseases. Mol Immunol. 2019;113:11–15.
   PubMed Web of Science ®Google Scholar
• Vigano S, Perreau M, Pantaleo G, et al. Positive and negative regulation of cellular immune responses in physiologic conditions and diseases. Clin Dev Immunol. 2012;2012:781.
   Google Scholar
• Wen Q, Zhou L, Chen H, et al. N-(3′, 4′ dimethoxycinnamonyl) anthranilic acid alleviated experimental colitis by inhibiting autoimmune response and inducing CD4+ CD25+ regulatory T cells production. J Gastroenterol Hepatol. 2013;28(8):1330–1338. Aug
   PubMed Web of Science ®Google Scholar
• Krystel-Whittemore M, Dileepan KN, Wood JG. Mast cell: a multi-functional master cell. Front Immunol. 2016;6:620–620.
   PubMed Web of Science ®Google Scholar
• Yin DD, Luo JH, Zhao ZY, et al. Tranilast prevents renal interstitial fibrosis by blocking mast cell infiltration in a rat model of diabetic kidney disease. Mol Med Rep. 2018;17(5):7356–7364.
   PubMed Web of Science ®Google Scholar
• Agier J, Pastwińska J, Brzezińska-Błaszczyk E. An overview of mast cell pattern recognition receptors. Inflamm Res. 2018;67(9):737–746.
   PubMed Web of Science ®Google Scholar
• Seto Y, Kato K, Tsukada R, et al. Protective effects of tranilast on experimental colitis in rats. Biomed Pharmacother. 2017;90:842–849.
   PubMed Web of Science ®Google Scholar
• Shimizu T, Kanai KI, Kyo Y, et al. Effect of tranilast on matrix metalloproteinase production from neutrophils in‐vitro. J Pharm Pharmacol. 2006;58(1):91–99.
   PubMed Web of Science ®Google Scholar
• Wang F, Hou H, Luo Y, et al. The laboratory tests and host immunity of COVID-19 patients with different severity of illness. JCI Insight. 2020;5(10):e137799.
   PubMed Web of Science ®Google Scholar
• Zuo Y, Yalavarthi S, Shi H, et al. Neutrophil extracellular traps (NETs) as markers of disease severity in COVID-19. medRxiv. 2020.
   Google Scholar
• De Biasi S, Meschiari M, Gibellini L, et al. Marked T cell activation, senescence, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia. Nat Commun. 2020;11(1):1–17.
   PubMed Web of Science ®Google Scholar
• Kato M, Takahashi F, Sato T, et al. Tranilast inhibits pulmonary fibrosis by suppressing TGFβ/SMAD2 pathway. Drug Des Devel Ther. 2020;14:4593.
   PubMed Web of Science ®Google Scholar
• Onoue S, Aoki Y, Kawabata Y, et al. Development of inhalable nanocrystalline solid dispersion of tranilast for airway inflammatory diseases. J Pharm Sci. 2011;100(2):622–633.
   PubMed Web of Science ®Google Scholar
• Kawabata Y, Yamamoto K, Debari K, et al. Novel crystalline solid dispersion of tranilast with high photostability and improved oral bioavailability. Eur J Pharm Sci. 2010;39(4):256–262.
   PubMed Web of Science ®Google Scholar
• Ishitsuka Y, Moriuchi H, Yang C, et al. Preventive effect of tranilast on oleic acid-induced lung injury in guinea pigs. Biol Pharm Bull. 2004;27(9):1451–1454.
   PubMed Web of Science ®Google Scholar
• Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033–1034.
   PubMed Web of Science ®Google Scholar
• Miao Y, Fan L, Li J-Y. Potential treatments for COVID-19 related cytokine storm – beyond corticosteroids. Front Immunol. 2020;11:1445–1445.
   PubMed Web of Science ®Google Scholar
• Matsumura T, Matsui M, Iwata Y, et al. A pilot study of tranilast for cardiomyopathy of muscular dystrophy. Intern Med. 2018;57(3):311–316.
   PubMed Web of Science ®Google Scholar
• Sun M, Yang F, Hou M. Successful treatment of scleredema diabeticorum with tranilast: three case reports. Diabetes Care. 2018;41(4):e40–e41.
   PubMed Web of Science ®Google Scholar